The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1

Oncogene

Volumn 25, Issue 12, 2006, Pages 1743-1752

  Abdul Ghani, R ^a   Serra, V ^a   Gyorffy B ^a   Jurchott K ^a   Solf, A ^a   Dietel, M ^a   Schafer R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Colon cancer; Doxorubicin; LY294002; Multi drug resistance associated protein MRP1; Phosphoinositol 3 kinase

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; DOXORUBICIN; GENISTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; UO 126; VERLUKAST;

APOPTOSIS; ARTICLE; CELL SURVIVAL; COLON CARCINOMA; DRUG MECHANISM; DRUG SENSITIZATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMONES; COLONIC NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MORPHOLINES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS;

EID: 33645038097     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209201     Document Type: Article

References (54)

1. Agullo G, Gamet-Payrastre L, Manenti S, Viala C, Remesy C, Chap H et al. (1997). Biochem Pharmacol 53: 1649-1657.
2. Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T. (2001). J Bioenerg Biomembr 33: 503-511.
3. Berg J, Tymoczko J, Stryer L. (2002). Biochemistry: Enyzmes, Basic Concepts and Kinetics, 5th edn. W.H. Freeman and Company: San Francisco.
4. Bos JL. (1989). Cancer Res 49: 4682-4689.
5. Brognard J, Clark AS, Ni Y, Dennis PA. (2001). Cancer Res 61: 3986-3997.
6. Burt RK, Garfield S, Johnson K, Thorgeirsson SS. (1988). Carcinogenesis 9: 2329-2332.
7. Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL et al. (2003). Int J Oncol 22: 469-480.
8. Chen TR, Drabkowski D, Hay RJ, Macy M, Peterson W. (1987). Cancer Genet Cytogenet 27: 125-134.
9. Chen Y, Sanchez Y. (2004). DNA Repair 3: 1025-1032.
10. Chen Z, Xiao Z, Chen J, Ng SC, Sowin T, Sham H et al. (2003). Mol Cancer Ther 2: 543-548.
11. Chin KV, Ueda K, Pastan I, Gottesman MM. (1992). Science 255: 459-462.
12. Clark AS, West K, Streicher S, Dennis PA. (2002). Mol Cancer Ther 1: 707-717.
13. Ding S, Chamberlain M, McLaren A, Goh L, Duncan I, Wolf CR. (2001). Br J Cancer 85: 1175-1184.
14. Di Simone D, Galimberti S, Basolo F, Ciardiello F, Petrini M, Scheper RJ. (1997). Anticancer Res 17: 3587-3592.
15. Filipeanu CM, Nelemans A, Veldman RJ, de Zeeuw D, Kok JW. (2000). FEBS Lett 474: 107-110.
16. Gekeler V, Ise W, Sanders KH, Ulrich WR, Beck J. (1995). Biochem Biophys Res Commun 208: 345-352.
17. Gewirtz DA. (1999). Biochem Pharmacol 57: 727-741.
18. Gottesman MM. (2002). Annu Rev Med 53: 615-627.
19. Gottesman MM, Fojo T, Bates SE. (2002). Nat Rev Cancer 2: 48-58.
20. Guise S, Braguer D, Carles G, Delacourte A, Briand C. (2001). J Neurosci Res 63: 257-267.
21. Györffy B, Serra V, Jürchott K, Abdul-Ghani R, Garber M, Stein U et al. (2005). Oncogene, Epub ahead of print.
22. Han JW, Dionne CA, Kedersha NL, Goldmacher VS. (1997). Cancer Res 57: 176-182.
23. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. (2002). Cancer Res 62: 1087-1092.
24. Jin W, Wu L, Liang K, Liu B, Lu Y, Fan Z. (2003). Br J Cancer 89: 185-191.
25. Kaushal GP, Kaushal V, Hong X, Shah SV. (2001). Kidney Int 60: 1726-1736.
26. Kim R. (2005). Cancer 103: 1551-1560.
27. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L et al. (2003). Oncogene 22: 3205-3212.
28. Kok JW, Veldman RJ, Klappe K, Koning H, Filipeanu CM, Muller M. (2000). Int J Cancer 87: 172-178.
29. Kopnin BP, Stromskaya TP, Kondratov RV, Ossovskaya VS, Pugacheva EN, Rybalkina EY et al. (1995). Oncol Res 7: 299-306.
30. Krasilnikov MA. (2000). Biochemistry 65: 59-67.
31. Lee JT, Steelman LS, McCubrey JA. (2004). Cancer Res 64: 8397-8404.
32. Liu XM, Wang LG, Kreis W, Budman DR, Adams LM. (2001). Br J Cancer 85: 1403-1411.
33. Mizutani H, Tada-Oikawa S, Hiraku Y, Kojima M, Kawanishi S. (2005). Life Sci 76: 1439-1453.
34. Nakashio A, Fujita N, Rokudai S, Sato S, Tsuruo T. (2000). Cancer Res 60: 5303-5309.
35. Nakashio A, Fujita N, Tsuruo T. (2002). Int J Cancer 98: 36-41.
36. Ng SS, Tsao MS, Chow S, Hedley DW. (2000). Cancer Res 60: 5451-5455.
37. Plasschaert SL, van der Kolk DM, de Boni ES, Kamps WA, Morisaki K, Bates SE et al. (2003). Clin Cancer Res 9: 5171-5177.
38. Rodenhuis S. (1992). Semin Cancer Biol 3: 241-247.
39. Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. (1991). J Immunol Methods 142: 257-265.
40. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D et al. (1990). J Natl Cancer Inst 82: 1107-1112.
41. Sklar MD. (1988). Science 239: 645-647.
42. Srivastava AK. (1985). Biochem Biophys Res Commun 131: 1-5.
43. Stavrovskaya AA. (2000). Biochemistry 65: 95-106.
44. Vanhaesebroeck B, Stein RC, Waterfield MD. (1996). Cancer Surv 27: 249-270.
45. van Zanden JJ, Geraets L, Wortelboer HM, van Bladeren PJ, Rietjens IM, Cnubben NH. (2004). Biochem Pharmacol 67: 1607-1617.
46. van Zuylen L, Nooter K, Sparreboom A, Verweij J. (2000). Invest New Drugs 18: 205-220.
47. Vlahos CJ, Matter WF, Hui KY, Brown RF. (1994). J Biol Chem 269: 5241-5248.
48. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP et al. (2000). Mol Cell 6: 909-919.
49. Wang Q, Li N, Wang X, Kim MM, Evers BM. (2002). Clin Cancer Res 8: 1940-1947.
50. Wang X, Martindale JL, Holbrook NJ. (2000). J Biol Chem 275: 39435-39443.
51. Xiao Z, Chen Z, Gunasekera AH, Sowin TJ, Rosenberg SH, Fesik S et al. (2003). J Biol Chem 278: 21767-21773.
52. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. (1996). Oncogene 13: 1359-1365.
53. Zhao Y, You H, Yang Y, Wei L, Zhang X, Yao L et al. (2004). J Cell Biochem 91: 621-632.
54. Zuber J, Tchernitsa O, Hinzmann B, Schmitz AC, Grips M, Hellriegel M et al. (2000). Nat Genet 24: 144-152.